
Biotts S.A.
Research and experimental development in natural sciences and engineering
Overview
Biotts is a biotech company specializing in transdermal drug delivery systems and its proprietary MTC-Y™ technology, which enables needle-free delivery of larger molecules such as peptides and proteins. It develops its own transdermal drug products and collaborates with the pharmaceutical industry, while also providing GMP-compliant R&D and laboratory services for pharmaceutical, biotechnology, cosmetics, and dietary supplement companies.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Sprawozdanie finansowe Spółki zostało sporządzone przy założeniu kontynuowania działalności gospodarczej przez co najmniej 12 miesięcy po dniu bilansowym. Biorąc pod uwagę aktualną sytuację Spółki, Zarząd Spółki identyfikuje okoliczności, które mogą powodować niepewności co do kontynuacji działalności. Spółka BIOTTS S.A. znajduje się nadal w fazie intensywnego rozwoju kluczowych produktów o istotnym potencjale i nie realizuje jeszcze powtarzalnych przychodów, sytuacja nie odbiega od lat ubiegłych. W 2025 roku Spółka rozpoczęła świadczenie usług badawczo-rozwojowych dla firm zewnętrznych, wykorzystując posiadane doświadczenie, zaplecze laboratoryjne oraz kapitał ludzki. W 2025 roku z tego typu działalności udało się uzyskać 298 tysięcy złotych przychodów netto. W 2026 roku spółka planuje zintensyfikować działania sprzedażowe i zwiększyć przychody w tym obszarze działalności. W roku zakończonym dnia 31 grudnia 2025 roku Spółka odnotowała stratę w kwocie 3 909 tysięcy zł. Natomiast bilans sporządzony na dzień 31 grudnia 2025 roku pokazuje dodatnią wartość kapitału obrotowego, w kwocie 679 tysięcy zł. Zgodnie z prognozami na 2026 r. Spółka zakłada zwiększenie wielkości sprzedaży, przy czym plan finansowy na 2026 r. zakłada stratę na podstawowej działalności gospodarczej – niemniej jednak kapitał własny na koniec roku 2026 nadal pozostanie na poziomie dodatnim. Spółka swoją działalność w 2025 r. i w latach wcześniejszych w głównym stopniu finansowała z wpływów z emisji akcji i dot
From the notes
| Contingent liabilities | Yes | |
| Shares in other companies |
|
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 92 days for 2025). All were audited by a statutory auditor.
- 202515/10/2026
- 202418/07/2025
- 202320/06/2024
- 202229/06/2023
- 202127/06/2022
- 202001/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

De-risking the clinical pathway: Biotts provides translational validation for the $13B chronic wound care market
The global chronic wound care market is currently valued at over $13 billion, driven by an urgent clinical need for more effective treatments for diabetic foot ulcers, pressure sores, and hard-to-heal surgical wounds. Despite the massive commercial potential, pharmaceutical pipelines in this space historically face high attrition rates, largely due to poor translational models that fail to accurately predict human clinical outcomes.

Data in Frontiers in Pharmacology shows Biotts' proprietary platform significantly outpaces standard antibiotic therapy in chronic wound care
Biotts has achieved a significant scientific and commercial milestone with the publication of new peer-reviewed data in the prestigious journal Frontiers in Pharmacology.

Biotts' New Study on Transdermal Lidocaine and Tetracaine in Pharmaceutics
Biotts publishes peer-reviewed research in Pharmaceutics (MDPI) validating MTC-Y™ technology for transdermal delivery of lidocaine and tetracaine.

Biotts Granted US Patent for MTC-Y Transdermal Carrier Technology
Biotts has been granted US Patent No. 12,478,679 B2 for its MTC-Y transdermal carrier technology. The patent was issued by the USPTO on 25 November 2025.

Biotts at BioJapan 2025 – Bringing Polish Transdermal Innovation to Asia
Biotts represented Polish transdermal innovation at BioJapan 2025 in Yokohama, Japan - Asia's premier bio-industry partnering event. Read about our experience.
Industry
Offer
- Pharmaceutical testing
- Drug development
- Formulation development
- Analytical research
- Stability testing
- Dietary supplement testing
- Laboratory services
Websites
- biotts.comThe global leader in transdermal drug delivery systemsWordPressGoogle AnalyticsGoogle Tag ManagerYoast SEOApache
Public procurement
3 tenders recorded as contractor, with a total value of $95,400.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Apr 20, 2026 | Research service involving in vivo testing of the elimination of Staphylococcus aureus from animal skin using the enzybiotic Aurezyna R, and research service involving the development of a measurement method... | $45,048$45,048 | Instytut Medycyny Doświadczalnej i Klinicznej Im. Mirosława Mossakowskiego Pan | |
| Oct 8, 2025 | Development of a formulation prototype | $49,855$49,855 | Instytut Medycyny Doświadczalnej i Klinicznej Im. Mirosława Mossakowskiego Pan | |
| Jul 25, 2025 | U/12/2025/B Organization and delivery of off-site training courses for the Faculty of Chemistry and Pharmacy | $497$497 | Uniwersytet Opolski |
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2020.
| Mark | Protected until | |
|---|---|---|
| BIOTTS (word) | Dec 29, 2030 |
Authorized Representatives
Manner of representation
Each member of the management board is entitled to represent the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-03-02.
08 1090 1522 0000 0001 4435 5412
23 1090 1522 0000 0001 6646 4352
44 1090 1522 0000 0001 4435 5443
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 36,858PLN 36,858 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Aug 21, 2026 | Commercial Companies Code notice | |
| Jul 1, 2026 | Shareholders' meeting convened | |
| Jun 13, 2019 | Commercial Companies Code notice |
Public aid
10 public aid cases recorded, with a total value of $4,589,696.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 10, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Sep 30, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Fundacja Instytut Studiów Wschodnich | |
| Nov 7, 2022 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Dolnośląska Agencja Rozwoju Regionalnego S.A. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-06-15 | Preparation by Biotts S.A. of a Eurogrant project planned for implementation under the EIC Pre-accelerator - Widening programme (HORIZON-WIDERA-2025-02) | $17,431$17,431 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| F1 Pharma S.A. | $272,113.66 | f1pharma.pl | ||
| Genelytica sp. z o.o. | $213,207.91 | genelytica.pl | ||
| TCI sp. z o.o. | $218,471.87 | tci.pl | ||
| Nanosanguis S.A. | $192,701.50 | nanosanguis.com | ||
| Countess Laboratories sp. z o.o. | $164,970.29 | countess.pl | ||
| Cofactor sp. z o.o. | $136,474.66 | cofactor.pl | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Meditransfer Centrum Transferu Technologii Iitd sp. z o.o. | $35,488.75 | iitd.pan.wroc.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-10-12 | Share capital increase (312,169.00 PLN → 1,248,676.00 PLN) | |
| 2026-03-13 | Share capital increase (311,385.00 PLN → 312,169.00 PLN) | |
| 2025-08-12 | Share capital increase (290,615.00 PLN → 311,385.00 PLN) | |
| 2025-05-23 | Share capital increase (287,060.00 PLN → 290,615.00 PLN) | |
| 2024-12-23 | Share capital increase (286,923.00 PLN → 287,060.00 PLN) |
FAQ
Last updated: 2026-10-21